-
-
-
-
-
-
-
Stifel Upgrades ChemoCentryx (CCXI) to Buy on Amendment To Avacopan NDA
-
-
-
-
-
-
-
ChemoCentryx (CCXI) Crashes 55% on Mixed AdComm Results, Gets Downgraded at Five Firms
-
-
-
-
-
-
-
ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights
-
-
-
-
-
-
-
ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
-
-
-
-
-
-
-
ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis
-
-
15,414 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

